Vident Advisory’s Edwards Lifesciences EW Stock Holding History

Vident Advisory’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$33.5M	Buy	418,892 +31,310	+8%	+$2.58M	0.29%	67
2025 Q4	$33M	Sell	387,582 -25,028	-6%	-$2.05M	0.3%	70
2025 Q3	$32.1M	Buy	412,610 +80,531	+24%	+$6.29M	0.31%	71
2025 Q2	$26M	Buy	332,079 +43,359	+15%	+$3.23M	0.29%	82
2025 Q1	$20.9M	Sell	288,720 -6,663	-2%	-$477K	0.31%	73
2024 Q4	$21.9M	Buy	295,383 +285,661	+2,938%	+$20M	0.38%	57
2024 Q3	$642K	Sell	9,722 -1,736	-15%	-$126K	0.02%	811
2024 Q2	$1.06M	Buy	11,458 +831	+8%	+$73.6K	0.03%	579
2024 Q1	$1.02M	Sell	10,627 -4,494	-30%	-$378K	0.02%	567
2023 Q4	$1.15M	Buy	15,121 +20	+0.1%	+$1.39K	0.03%	520
2023 Q3	$1.05M	Buy	+15,101	New	+$1.21M	0.03%	493

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vident Advisory's EW Position: Q1 2026 in Review

Vident Advisory increased its Edwards Lifesciences (EW) stake by 8.1% in Q1 2026, buying an estimated $2.58M and bringing the position to 418,892 shares worth $33.5M. The position accounts for 0.29% of the portfolio, ranked #67.

Vident Advisory first reported a position in EW in Q3 2023 and has held it in 11 quarters since. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Vident Advisory held 418,892 shares of Edwards Lifesciences worth $33.5M as of Q1 2026.
Vident Advisory bought 31,310 Edwards Lifesciences shares in Q1 2026, an estimated $2.58M.
Edwards Lifesciences made up 0.29% of Vident Advisory's portfolio in Q1 2026, its #67 holding.
Vident Advisory first reported a position in Edwards Lifesciences in Q3 2023 and has held it in 11 quarters since.
1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.